

Title (en)
2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)QUINOXALIN-5(6H)ONE DERIVATES BEING 5HT2C AGONISTS

Title (de)
2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)CHINOXALIN-5(6H)ONE DERIVATE ALS 5HT2C AGONISTEN

Title (fr)
DERIVES DE 2,3,4,4A-TETRAHYDRO-1H-PYRAZINO(1,2-A)QUINOXALIN-5(6H)ONE UTILISES EN TANT QU'AGONISTES DE 5HT2C

Publication
EP 1140940 A1 20011010 (EN)

Application
EP 99965285 A 19991216

Priority
• US 9929894 W 19991216
• US 21347198 A 19981217

Abstract (en)
[origin: WO0035922A1] This invention provides compounds of formula (I), and enantiomers thereof, wherein R is hydrogen or alkyl of 1-6 carbon atoms; R' is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, -CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; X is CR5R6 or a carbonyl group; R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen; which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, type II diabetes, and epilepsy.

IPC 1-7
C07D 487/04; **A61K 31/495**; **A61P 25/00**

IPC 8 full level
A61K 31/4985 (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 25/00** (2006.01); **A61P 25/06** (2006.01); **A61P 25/08** (2006.01); **A61P 25/18** (2006.01); **A61P 25/20** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **C07D 487/04** (2006.01)

CPC (source: EP KR)
A61P 3/04 (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 25/06** (2018.01 - EP); **A61P 25/08** (2018.01 - EP); **A61P 25/18** (2018.01 - EP); **A61P 25/20** (2018.01 - EP); **A61P 25/22** (2018.01 - EP); **A61P 25/24** (2018.01 - EP); **C07D 487/04** (2013.01 - EP KR)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0035922 A1 20000622; AR 022687 A1 20020904; AU 3123400 A 20000703; BR 9916326 A 20011002; CA 2351385 A1 20000622; CN 1240701 C 20060208; CN 1330652 A 20020109; CZ 20012193 A3 20011212; EA 200100671 A1 20011224; EP 1140940 A1 20011010; HU P0104773 A2 20020429; HU P0104773 A3 20041028; IL 143323 A0 20020421; JP 2002532504 A 20021002; KR 20010108025 A 20011207; NO 20013001 D0 20010615; NO 20013001 L 20010615; NZ 512765 A 20031031; PL 348815 A1 20020617; SK 8192001 A3 20011203; ZA 200104598 B 20020905

DOCDB simple family (application)
US 9929894 W 19991216; AR P990106455 A 19991216; AU 3123400 A 19991216; BR 9916326 A 19991216; CA 2351385 A 19991216; CN 99814416 A 19991216; CZ 20012193 A 19991216; EA 200100671 A 19991216; EP 99965285 A 19991216; HU P0104773 A 19991216; IL 14332399 A 19991216; JP 2000588181 A 19991216; KR 20017007583 A 20010616; NO 20013001 A 20010615; NZ 51276599 A 19991216; PL 34881599 A 19991216; SK 8192001 A 19991216; ZA 200104598 A 20010605